文献速递脊柱关节炎

司库奇尤单抗治疗非放射学中轴型脊柱关节炎的III期研究主要结果

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
PubMed 文献 · Arthritis Rheumatol · 2020-11-24

PREVENT是首个评估司库奇尤单抗治疗活动性非放射学中轴型脊柱关节炎(nr-axSpA)的III期研究,共随机555例患者。结果显示,TNFi初治患者中,负荷剂量组第16周ASAS40应答率41.5%、非负荷剂量组第52周39.8%,均显著高于安慰剂组(29.2%和19.9%,P<0.05)。司库奇尤单抗150mg在52周内持续改善症状且安全性与此前报告一致。

要点

  • 司库奇尤单抗150mg在TNFi初治nr-axSpA患者中显著提高ASAS40应答率
  • 负荷剂量组第16周ASAS40应答率41.5%,非负荷剂量组第52周39.8%
  • 52周内安全性与既往报告一致,未发现新安全性信号

核心结论

  • 司库奇尤单抗150mg可显著且持续改善非放射学中轴型脊柱关节炎患者的体征和症状至52周。
  • 安全性特征与既往报告一致,未发现新的安全性问题。

研究设计与样本

  • PREVENT研究为随机、安慰剂对照III期研究,共随机555例活动性非放射学中轴型脊柱关节炎患者。
  • 患者按1:1:1随机接受司库奇尤单抗150mg负荷剂量、司库奇尤单抗150mg非负荷剂量或安慰剂,皮下给药。
  • 第20周后允许切换至开放标签司库奇尤单抗或标准治疗。
  • 研究设两套独立分析计划,分别符合欧盟和非美监管要求(计划A,第16周)及美国监管要求(计划B,第52周)。

主要发现

  • TNFi初治患者中,负荷剂量组第16周ASAS40应答率为41.5%,非负荷剂量组第52周为39.8%,安慰剂组分别为29.2%和19.9%(均P<0.05)。
  • 第16周时主要终点和所有次要终点均达到。
  • 完成52周治疗的患者共481例,负荷剂量组84.3%(156/185)、非负荷剂量组89.7%(165/184)、安慰剂组86.0%(160/186)。
  • 第20至48周期间切换至开放标签或标准治疗的比例:负荷剂量组50.8%、非负荷剂量组47.3%、安慰剂组64.0%。

关键数值与推荐

  • 主要终点为TNFi初治患者中负荷剂量组第16周、非负荷剂量组第52周的ASAS40应答率。
  • ASAS40应答率比较:负荷剂量组第16周41.5% vs 安慰剂29.2%;非负荷剂量组第52周39.8% vs 安慰剂19.9%(均P<0.05)。

临床怎么用

  • 对于活动性非放射学中轴型脊柱关节炎且TNFi初治的患者,司库奇尤单抗150mg可考虑作为治疗选择。
  • 负荷剂量方案第16周即可观察到显著疗效,非负荷剂量方案第52周亦显示显著疗效。
  • 治疗52周内安全性与既往报告一致,可在此类患者中持续使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non-loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. The NL group received placebo at weeks 1, 2, and 3 to maintain blinding. Switch to open-label secukinumab or standard of care was permitted after week 20. The study had 2 independent analysis plans, per European Union and non-US (plan A; week 16) and US (plan B; week 52) regulatory requirements. The primary end point was 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society (ASAS40) criteria at week 16 (in the LD group) and at week 52 (in the NL group) in tumor necrosis factor inhibitor (TNFi)-naive patients. Safety analyses included all patients who received ≥1 dose of study treatment. RESULTS: Overall, 481 patients completed 52 weeks of treatment, including 84.3% (156 of 185) in the LD group, 89.7% (165 of 184) in the NL group, and 86.0% (160 of 186) in the placebo group. The proportion of patients who switched to open-label or standard of care between weeks 20 and 48 was 50.8% in the LD group, 47.3% in the NL group, and 64.0% in the placebo group. Both primary and all secondary end points were met at week 16. The proportion of TNFi-naive patients who met ASAS40 was significantly higher for LD at week 16 (41.5%) and NL at week 52 (39.8%) versus placebo (29.2% at week 16 and 19.9% at week 52; both P < 0.05). No new safety findings were reported. CONCLUSION: Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2020. PMID: 32770640. doi:10.1002/art.41477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。